Still Waiting for Its Blockbuster

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

It could have been worse. In fact, this morning, it was.

Amgen (Nasdaq: AMGN  ) is down about 1% as I write, having been down about 3% earlier. The stock's saving grace? Amgen's announcement of a Food and Drug Administration delay for its long-awaited osteoporosis drug, Prolia (its treatment for postmenopausal osteoporosis), contained this statement: "This letter does not require additional pre-marketing clinical trials to complete the review of the treatment indication."

The agency does want a new trial before it'll approve Prolia for the prevention of osteoporosis, but that's to be expected, given the results of the FDA advisory panel meeting.

To be approved to treat osteoporosis, Amgen needs to give the FDA some additional information, including more details on how it plans to monitor side effects after the drug is approved. Just by the FDA's request for that information, you can tell that Amgen is on the home stretch.

The company didn't say how long it'll take to turn in the requested information and get a response back from the FDA. I'd guess a few months, at a minimum. This is welcome news for other drugmakers of osteoporosis treatments, like GlaxoSmithKline's (NYSE: GSK  ) and Roche's Boniva, Procter & Gamble's (NYSE: PG  ) and sanofi-aventis' (NYSE: SNY  ) Actonel, and even generic-drug makers that sell versions of Merck's (NYSE: MRK  ) Fosamax.

The FDA's focus on safety with Prolia, including requiring Amgen to have a Risk Evaluation and Mitigation Strategy (REMS), could also be seen as a good sign for competitors. The osteoporosis market is extremely competitive, and a newcomer with a less-established side effect profile could be at a disadvantage.

On the other hand, Prolia is likely to excel in treating cancer patients whose tumors have spread to their bones. That indication is a little farther behind in development, but the data looks good so far, with Prolia beating Novartis' (NYSE: NVS  ) Zometa in one trial. With less competition in this indication, Prolia will likely have an easier time marketing the drug.

And so it's back to waiting for Amgen's investors. Tick-tock. Tick-tock.

Procter & Gamble is a Motley Fool Income Investor recommendation. Novartis is a Global Gains pick. Try any of our Foolish newsletters today, free for 30 days

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool owns shares of Procter & Gamble and has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1010794, ~/Articles/ArticleHandler.aspx, 10/27/2016 5:44:27 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 8 hours ago Sponsored by:
DOW 18,199.33 30.06 0.17%
S&P 500 2,139.43 -3.73 -0.17%
NASD 5,250.27 -33.13 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 4:00 PM
AMGN $158.99 Up +1.10 +0.69%
Amgen CAPS Rating: ****
GSK $40.34 Up +0.02 +0.05%
GlaxoSmithKline CAPS Rating: ***
MRK $60.87 Down -1.08 -1.74%
Merck and Co. CAPS Rating: ****
NVS $71.13 Down -1.50 -2.07%
Novartis CAPS Rating: ****
PG $87.40 Up +0.43 +0.49%
Procter and Gamble CAPS Rating: ****
SNY $37.06 Down -0.33 -0.88%
Sanofi CAPS Rating: *****